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A B S T R A C T
The emersion of the new coronavirus SARS COV 2 (Severe Acute Respiratory Syn-
drome Coronavirus 2) was rapidly characterized as a pandemic by WHO. The major 
manifestation of the virus is respiratory distress; however, the involvement of other or-
gans should not be overlooked. The kidney is one of the most important target organs 
of the specific virus with acute kidney injury (AKI) described in 5-36% of COVID 
positive patients and an average 25% within the severely ill.
PuRPoSe: The purpose of this study was to consider the incidence of AKI in patients 
with COVID 19 in our cohort and to better understand risk factors associated with 
AKI. Further, we wanted to investigate the impact of AKI on survival and in hospital 
mortality.
MeThodS: Patients admitted to Evagelismos General Hospital with confirmed COV-
ID-19 infection from 11th March until 22th May were investigated. Patients 18 years 
old as well as transplanted patients were excluded from this study. AKI was defined 
according to the AKI criteria.
ReSulTS: From 99 patients with COVID-19 infection, AKI occurred in 41 (41.4%). 
A total of 44 patients (44.4%) were admitted to Intensive Care Unit (ICU) and 31 of 
them (70.5%) developed AKI. Of the 44 patients with AKI, 16 (39%) required renal 
replacement therapy. Hospital mortality, in total, was 16.2% (37% among patients 
with AKI versus 0.02% among those without AKI, p=0.000).
ConCluSion: AKI was common among patients hospitalized with COVID 19. AKI 
was associated with older age, clinical severity and existing CKD.
i n T R o d u C T i o n
The outbreak of COVID 19, which was initially reported in Wuhan, China as a 
rising number of cases of unknown origin pneumonia had rapidly a pandemic spread 
worldwide. Severe Acute Respiratory Syndrome coronavirus 2 (SARS-COV-2) is a 
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novel coronavirus belonging to the already known beta coro-
navirus cluster associated with the Severe Acute Respiratory 
Syndrome (SARS) and the Middle East Respiratory Syndrome 
(MERS) and consists the pathogen of coronavirus disease 
(COVID 19)1,2. Since initial detection more than 140 million 
cases have been confirmed to date. The clinical spectrum of 
COVID 19 can range from asymptomatic to severe disease 
with critical illness and high mortality. Although pulmonary 
complications are the initial clinical sign and the leading 
cause of admission to an Intermediate Care Unit (ICU) with 
a consequent high mortality, many other organs may also be 
affected. There is growing evidence that acute kidney injury is 
prevalent in COVID-19 patients and its presence is associated 
with poor prognosis3,4. In already published studies the percent-
age of patients hospitalized with COVID-19 presenting AKI 
ranges from 5 to 36 %, while approaches a rate of 90% among 
patients on mechanic ventilation3. In Greece the first case of 
a 38 year old female patient with travel history to northern 
Italy was reported on the 26th of February. To date more than 
300.000 cases and 3092 deaths have been reported in Greece. 
Aim of this study was to define the incidence of AKI among 
patients with COVID-19 and define predisposing risk factors 
indicating potential approaches for risk stratification. 
M A T e R i A l S  A n d  M e T h o d S
PA T i e n T S
In March 2020 and after the first reported cases of COV-
ID-19 infection in Greece, Evagelismos General Hospital was 
designated as one of the reference hospitals in Athens for 
treatment of COVID-19 patients. Critically ill patients were 
hospitalized under isolation precautions in an intensive care 
unit (ICU) while patients with mild or moderate disease were 
admitted in an isolated ward. The study was approved from the 
medical ethical committee of Evagelismos General Hospital 
(Approval Number 156) while oral consent was obtained from 
all patients or relatives. The different clinical categories for 
the severity of the disease and the definition of COVID-19 
infection were defined according to the WHO guidelines5. 
Patients younger than 18, those with end stage kidney disease 
on hemodialysis or peritoneal dialysis and kidney transplant 
recipients were excluded from the study.
S T u d y  d e f i n i T i o n S 
Symptomatic patients without evidence of viral pneumonia 
or hypoxia were considered to have mild disease while those 
with clinical signs of pneumonia such as fever, cough, dyspnea, 
shortness of breath but no signs of severe pneumonia, including 
SpO2 ≥90% on room air had a moderate disease. For severe 
pneumonia the presence of clinical signs of pneumonia plus 
one of the following: respiratory rate >30 breaths/min, severe 
respiratory distress or SpO2 <90% on room air was manda-
tory. ARDS, sepsis or septic shock with persistent hypotension 
despite volume resuscitation requiring vasopressors with organ 
dysfunction caused by a dysregulated host response to infection 
were present in critically ill patients.
AKI was identified using KDIGO (Kidney Disease Im-
proving Global Outcomes) definition. Defined when serum 
creatinine increases by 0.3 mg/dl or more in 48 h or rises to at 
least 1.5-fold from baseline within 7 days. 
The collected information included demographic data, 
exposure history, medication, comorbidities, chest computer 
tomography reports and treatment. The day on which symp-
toms appeared was defined as the onset date. The clinical 
outcomes were documented until May, the 22nd.
The baseline characteristics on hospital admission are 
listed on table 1.
S T u d y  d e S i G n  A n d  C o h o R T
In this retrospective, single center study we analyzed data 
from electronic medical records. We obtained epidemiological, 
clinical, laboratory and radiological data and renal outcomes 
of 99 patients with COVID-19 admitted from March 11th to 
Table 1. Baseline demographic characteristics, comor-
bidities and laboratory findings on hospital admission, 
BMI, body mass index, DM diabetes mellitus, CAD Coro-
nary artery disease, COPD chronic obstructive pulmonary 
disease, HF heart failure
COVID +
aKI non aKI p-value
Sex (male, %) 31 (75.6) 35 (60.3) 0.08
Age (sd) 69.35 (12) 59.45 (16) 0.001
BMI (sd) 28.2 (3.6) 28.4 (5.8) NS
DM (%) 12 (29.3) 5 (0.09) 0.01
Dyslipidemia (%) 20 (49) 14 (25) 0.025
CAD (%) 9 (22) 5 (0.09) 0.07
COPD (%) 6 (14.6) 4 (0.07) NS
HF (%) 12 (29.3) 3 (0.05) 0.001
Smoke (%) 10 (25.6) 11 (21.6) NS
CKD-EPI (sd) ml/min 64 (27.7) 89.9 (21.85) 0.000
Hb (sd) g/dl 11.98 (2.3) 12.8 (1.85) 0.075
Ferritin (sd) ng/ml 221.6 (195.4) 272.31 (322.3) NS
CRP (sd) mg/l 13.5 (11.8) 9.1 (10) 0.065
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May 22nd. COVID-19 was present on admission or diagnosis 
was confirmed during hospitalization. Real time PCR (Poly-
merase chain reaction) testing of a nasopharyngeal sample 
for COVID-19 was performed either in our hospital or in the 
Hellenic Pasteur Institute. As primary end point was defined 
AKI during hospitalization. 
S T A T i S T i C A l  A n A ly S i S 
Statistical analysis was carried out using SPSS 24.0 pro-
gram. Baseline characteristics were described using mean ± 
standard deviation (SD) for continuous variables or frequen-
cies with percentage for categorical variables. Continuous 
variables were compared between groups using the student’s 
t-test or ANOVA, as appropriate. Categorical variables were 
compared between groups using the Chi-squared test. AKI-
censored survival outcomes were estimated using the Kaplan–
Meier method with significance tested using the log-rank test. 
Multivariable analysis was performed to adjust for covariates 
associated with outcomes of interest with p <0.05 in univariate 
analysis. All p-values were two-tailed, and p-values of <0.05 
were considered significant.
R e S u l T S
d e M o G R A P h i C  C h A R A C T e R i S T i C S
A total of 99 patients (67% men and 33% women) with 
confirmed COVID 19 infection were included in the study with 
mean age (63.57 ± 15.3 years). 44 of the confirmed cases were 
admitted in an ICU while 55 in an isolated ward. The mean age 
was 66.56 ± 10.2 years for the ICU patients (35 men, 79.5%) 
and 61.5 ± 18 for the non ICU patients respectively (Figure 1). 
C l i n i C A l  M A n i f e S T A T i o n S  
A n d  C o M o R B i d i T i e S
The symptoms on admission are shown in Table 2. We 
studied various baseline characteristics on our cohort. Poten-
tial risk factors predicting AKI was the age and the CKD- EPI 
on admission (p 0.001 and 0.000 respectively). Factors like 
the median time from symptoms onset, admission, PCR test-
ing to developing AKI or exposure history had no impact on 
development of AKI. 
From the reported comorbidities dyslipidemia and dia-
betes were positively correlated with AKI (0.025 and 0.010 
respectively) while other factors like BMI, sex and smoking 
had no correlation. 
From the symptoms on admission fatigue (p-value 0.031), 
diarrhea (p-value 0.032), dyspnea (p-value 0.045) and vomit-
ing (p-value 0.028) were positive correlated with AKI in our 
cohort. All patients with AKI had received an antibiotic pre-
treatment (p-value 0.000).
l A B o R A T o R y  A n d  R A d i o l o G i C A l 
PA R A M e T e R S
Extended laboratory testing was performed on admission. 
Except of the CKD- EPI on admission, which was positively 
correlated with the development of AKI, the remaining tested 
laboratory values had no statistical significance with the de-
velopment of acute kidney injury. On figure 2 is documented 
the mean creatinine value for ICU and non ICU patients in 
5- day intervals. There was a trend for higher ferritin levels on 







Non ICU  
(%, total)
p-value
Cough 28 (28.3) 32 (32.3) NS
Sputum 10 (10.3) 8 (8.2) NS
Anosmia 0 1 (1) NS
Ageusia 0 1 (1) NS
Myalgia 2 (2) 2 (2) NS
Fatigue 11 (11.1) 6 (6.1) 0.057
Diarrhea 4 (4.1) 9 (9.3) NS
Fever 41 (42.3) 52 (53.6) NS
Dyspnea 32 (33) 21 (21.6) 0.000
Nausea/Vomit 3 (3.1) 7 (7.2) NSfiGuRe 1. Flowchart showing the study population, AKI acute 
kidney injury, COVID 19, Coronavirus Disease 19.
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dysfunction caused by a dysregulated host response to infec-
tion. All of them developed respiratory failure and required 
mechanic ventilation. All mentioned factors were positively 
correlated with AKI (p-value 0.000). The days from admission 
until sepsis onset and consequently the severity of the disease 
were negative correlated with presence of AKI (p value 0.037). 
15 patients from our cohort died (16.2%), 14 of them in ICU.
d i S C u S S i o n 
Although SARS COV 2 preferentially affects the res-
piratory tract, kidney involvement is frequent with clinical 
presentation ranging from mild proteinuria and hematuria to 
progressive acute kidney injury6. In CRTs the percentage of 
acute kidney injury varies from 5 to 36 %3,7. This variation may 
be explained in part by varying populations and percentage 
of severely ill patients in the cohorts or hospital practices and 
differences on admission threshold. 
In our cohort 41% of the admitted patients with COVID 
19 developed AKI while 44% of them were critically ill. 16% 
of COVID patients with AKI died. The impact of AKI on mor-
tality was demonstrated in previous reports showing that the 
proportion of patients with severe outcomes is high in patients 
with AKI and severe disease. The incidence of AKI was higher 
in older patients and in those with elevated baseline creatinine 
(p value 0,001 and 0,000 respectively) suggesting that greater 
age and kidney disease on admission are both associated with 
poor outcomes, finding in keeping with previous studies6. A 
prospective study in China with 701 patients admitted in a 
tertiary teaching hospital showed that AKI occurred in 5.1% 
while the incidence of in hospital death was higher for patients 
with elevated baseline creatinine on admission4. Most of the 
cases of AKI occurred within 7 days.
The mean time period from the symptoms onset to devel-
opment of AKI in our cohort was 12.37±10.7. Monitoring of 
kidney function and awareness of AKI is therefore important 
and earlier admission or consultancy of a health care profes-
sional may prevent negative clinical outcomes
The pathogenesis of AKI could be the result of the syn-
ergistic effect of the renal tropism of SARS COV-2 and the 
cytokine induced systemic inflammatory response in severe 
disease. Acute tubular necrosis (ATN) has been the predomi-
nant lesion described in multiple histopathologic series.
Arterial underfilling and tissue hypoxia due to multiorgane 
failure and shock and also drug toxicity and administration 
of contrast fluid as well as additive prerenal factors through 
volume depletion could contribute to development of AKI. 
Autopsy studies have confirmed with immunohistochemistry 
the presence of SARS-CoV-2 nucloeocapsid protein in the 
renal tubule8,9. Moreover, the receptor of SARS-CoV-2, 
(angiotensin converting enzyme) ACE2 was found to be up-
regulated in patients with COVID-19. The viral spike protein 
admission with severe outcomes but not statistical significant. 
All patients had a chest x ray on admission and most of 
them a Computer tomography during hospitalization. The 
typical findings were bilateral pulmonary infiltrates in 68.2% of 
the patients, ground glass opacities in 20.5% and consolidation 
in 6.8%. Only five patients who were not critically ill and were 
hospitalized in the isolated ward had no radiological findings.
C l i n i C A l  o u T C o M e S
AKI was reported in 41 COVID patients (41.4%), 31 of 
them (31.3% of our total cohort) hospitalized in the ICU. 
The mean age of the COVID patients who developed AKI 
was 69.35±12.1 years, statistically significant higher from 
COVID patients who did not develop an AKI (59.45 ± 16.1 y, 
p-value 0.001). The same age difference was also reported to 
the ICU patients with those presenting AKI being older than 
the patients who preserved their kidney function (p 0.035). 
47% developed AKI stage I, 3% AKI Stage II and 50% AKI 
Stage III. The mean time of development of AKI after hospital 
admission was 8.3±10.3 days for the whole cohort and for the 
ICU patients was 12.37±10 days.
Sixteen patients required renal replacement therapy. All 
of them were critically ill. The modality utilized was continu-
ous renal replacement therapy (CRRT). The mean time of 
initiation of CRRT from the onset of respiratory failure and 
mechanic ventilation was 2.32±5.12 days.
From the ICU 27 patients (61.4%) developed sepsis, 19 
(43.2%) septic shock defined as persistent hypotension de-
spite volume resuscitation requiring vasopressors with organ 
fiGuRe 2. Course of average creatinine values for ICU and non 
ICU patients in 5-day intervals after admission.
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binds to ACE 2 receptors and this interaction facilitates entry 
of the virus in the human cells. ACE 2 gene is expressed in the 
kidney10 while Wrapp et al described that the affinity of SARS 
COV 2 to the ACE2 receptor is 10-20 times higher than the 
one of SARS COV11. The role of cytokine releasing syndrome 
in developing of AKI is still to be elucidated. 
The contribution of each of the previously announced fac-
tors to the pathogenesis of AKI is still to be clarified.
We confirmed that several comorbidities were independent 
risk factors for AKI.
Nineteen (19) % of patients in our study had diabetes Typ 
II, 43% hypertension and 17% Coronary Heart Disease. Vari-
ations in the prevalence of comorbidities have been reported 
in previous reports17. (Three) 3% of our patients were treated 
with ACE inhibitors (ACEI) and 28% with Angiotensin recep-
tor blockers (ARB) according to the current guidelines. Both 
drug groups are shown to increase the ACE2 expression in the 
kidney and the heart (2-5 fold)18,19. It still remains controversial 
whether the use of these drugs could predispose to more severe 
illness. Angiotensin II is catalyzed by ACE 2 to angiotensin 
(1-7) with anti-inflammatory and vasodilatory effects20. Many 
studies could not support a negative prognosis while other 
studies have suggested that ACE inhibitors may upregulate 
the expression of ACE2, exacerbate the anti-inflammatory 
effects and lead to more severe infection21-23.
Our data could not support worse outcomes for patients in 
ACEI or ARB. The official statement by the European Society 
of Hypertension (ESH) and Cardiology (ESC) is the critical 
use of these agents in patients with reduced renal function and 
hemodynamic instability. From the other side, RAAS blockers 
should not be discontinued when indicated in stable patients 
with confirmed COVID 19 infection.
From the patients with AKI in our study 16 (39%) required 
RRT, which was delivered as continuous renal replacement 
therapy (CRRT). All of the patients needed CRRT were 
hospitalized in the ICU. From the non ICU patients only one 
developed AKI Stage III but did not need renal replacement 
therapy. 
The proportion of patients needed CRRT ranges from 
1.5-9 % in cohorts, while in severely ill patients the percentage 
can rise to 5.2-25 %1,6,13. 
Ronco et al describe the extracorporal modalities used for 
blood purification14. 
CRRT or slow low efficiency dialysis (SLED) if avail-
able has been practiced in many sepsis patients on mechanic 
ventilation. Intermittent hemodialysis is not preferred in the 
setting of isolation and the hemodynamic instability present-
ing in severely ill patients15. Cytokine adsorption columns for 
patients with cytokine releasing syndrome and their potential 
in removing inflammatory agents can be used for the treatment 
of severe COVID-1916.
Our study has some notable limitations. Incomplete 
documentation and lacking data of the exposure history and 
the symptoms on admission especially in cases diagnosed in 
outpatient setting was due to the retrospective design of our 
study inevitable. At the time of data extraction 5 severely ill 
patients were still hospitalized and the outcomes considered 
were the outcomes of the time of the analysis. Moreover we 
did not have access to urine analysis results and therefore we 
could not provide data regarding proteinuria and hematuria. 
Due to the relatively short observation period we were unable 
to obtain long term outcomes. 
C o n C l u S i o n
The incidence of AKI in COVID 19 patients is high and 
is associated with comorbidities such as diabetes and chronic 
kidney disease. Hospital mortality and severe outcomes are 
significantly higher in AKI patients.
Patients with COVID 19 should be closely monitored 
during hospitalization for the development of AKI. Further 
studies may elucidate new markers for early detection of kidney 
damage and determine a more effective clinical approach. 
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